Search for other papers by Dongyan Han in
Google Scholar
PubMed
Search for other papers by Min Ding in
Google Scholar
PubMed
Search for other papers by Rongli Xie in
Google Scholar
PubMed
Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
Search for other papers by Zhengshi Wang in
Google Scholar
PubMed
Search for other papers by Guohui Xiao in
Google Scholar
PubMed
Search for other papers by Xiaohong Wang in
Google Scholar
PubMed
Search for other papers by Lei Dong in
Google Scholar
PubMed
Shanghai Center of Thyroid Diseases, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
Search for other papers by Zhiqiang Yin in
Google Scholar
PubMed
Research Institute of Pancreatic Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China
Institute of Translational Medicine, Shanghai Jiao Tong University, Shanghai, China
Search for other papers by Jian Fei in
Google Scholar
PubMed
between cytological examination and molecular testing for thyroid nodules Next, whether the 18-gene test panel could predict malignancy was examined. There were 140 samples that could be used for calculating the diagnostic efficiency, which was
Search for other papers by Klaudia Zajkowska in
Google Scholar
PubMed
Search for other papers by Janusz Kopczyński in
Google Scholar
PubMed
Search for other papers by Stanisław Góźdź in
Google Scholar
PubMed
Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland
Search for other papers by Aldona Kowalska in
Google Scholar
PubMed
tumour should be examined to exclude the presence of papillary structures. In addition, secondary criteria (molecular testing for BRAF V600E and other high-risk mutations and immunohistochemistry for BRAF V600E) were added that may be helpful but are
Search for other papers by Irfan Vardarli in
Google Scholar
PubMed
Search for other papers by Susanne Tan in
Google Scholar
PubMed
Search for other papers by Rainer Görges in
Google Scholar
PubMed
Search for other papers by Bernhard K Krämer in
Google Scholar
PubMed
Search for other papers by Ken Herrmann in
Google Scholar
PubMed
Search for other papers by Christoph Brochhausen in
Google Scholar
PubMed
, there is a need to avoid unnecessary thyroid surgery. The guidelines recommend the use of molecular tests for further management of thyroid nodules with indeterminate cytology (ITN); however, for the choice of the suitable method and the interpretation
Search for other papers by Elizabeth J de Koster in
Google Scholar
PubMed
Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
Division of Clinical Studies, Institute of Cancer Research, London, UK
Search for other papers by Olga Husson in
Google Scholar
PubMed
Search for other papers by Eveline W C M van Dam in
Google Scholar
PubMed
Search for other papers by G Sophie Mijnhout in
Google Scholar
PubMed
Search for other papers by Romana T Netea-Maier in
Google Scholar
PubMed
Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands
Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy
Search for other papers by Wim J G Oyen in
Google Scholar
PubMed
Search for other papers by Marieke Snel in
Google Scholar
PubMed
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands
Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands
Search for other papers by Lioe-Fee de Geus-Oei in
Google Scholar
PubMed
Search for other papers by Dennis Vriens in
Google Scholar
PubMed
Search for other papers by for the EfFECTS trial study group in
Google Scholar
PubMed
diagnostic surgery for approximately 75% benign nodules, a range of additional diagnostics is currently available, including various ultrasound classification systems, molecular testing, and 2-[ 18 F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT ( 4 , 5 , 6 ). Our
Search for other papers by Barbora Pekova in
Google Scholar
PubMed
Search for other papers by Sarka Dvorakova in
Google Scholar
PubMed
Search for other papers by Vlasta Sykorova in
Google Scholar
PubMed
Search for other papers by Gabriela Vacinova in
Google Scholar
PubMed
Search for other papers by Eliska Vaclavikova in
Google Scholar
PubMed
Search for other papers by Jitka Moravcova in
Google Scholar
PubMed
Search for other papers by Rami Katra in
Google Scholar
PubMed
Search for other papers by Petr Vlcek in
Google Scholar
PubMed
Search for other papers by Pavla Sykorova in
Google Scholar
PubMed
Search for other papers by Daniela Kodetova in
Google Scholar
PubMed
Search for other papers by Josef Vcelak in
Google Scholar
PubMed
Search for other papers by Bela Bendlova in
Google Scholar
PubMed
variants should also be detected, which could be another trigger of thyroid cancer. The genetic molecular testing seems to be the benefit for pediatric patients for their diagnosis and prognosis. Hopefully, it will improve the quality of life of pediatric
Search for other papers by Mahmoud Al-Masri in
Google Scholar
PubMed
Search for other papers by Tawfiq Al-Shobaki in
Google Scholar
PubMed
Search for other papers by Hani Al-Najjar in
Google Scholar
PubMed
Search for other papers by Rafal Iskanderian in
Google Scholar
PubMed
Search for other papers by Enas Younis in
Google Scholar
PubMed
Search for other papers by Niveen Abdallah in
Google Scholar
PubMed
Search for other papers by Abdelghani Tbakhi in
Google Scholar
PubMed
Search for other papers by Hussam Haddad in
Google Scholar
PubMed
Search for other papers by Mohammad Al-Masri in
Google Scholar
PubMed
Search for other papers by Zeinab Obeid in
Google Scholar
PubMed
Search for other papers by Awad Jarrar in
Google Scholar
PubMed
Committee on Cancer (AJCC) staging system. Molecular testing for somatic genetic changes All the retrieved hematoxylin and eosin (H&E) stained sections for the cohort cases were reviewed separately by two experienced histopathologists at the
Search for other papers by Danielle Christine Maria van der Kaay in
Google Scholar
PubMed
Search for other papers by Anne Rochtus in
Google Scholar
PubMed
Search for other papers by Gerhard Binder in
Google Scholar
PubMed
Search for other papers by Ingo Kurth in
Google Scholar
PubMed
Search for other papers by Dirk Prawitt in
Google Scholar
PubMed
Search for other papers by Irène Netchine in
Google Scholar
PubMed
Department of Endocrinology at Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Anita C S Hokken-Koelega in
Google Scholar
PubMed
Search for other papers by Miriam Elbracht in
Google Scholar
PubMed
Search for other papers by Thomas Eggermann in
Google Scholar
PubMed
have exponentially increased our understanding of the underlying causes of short stature, but despite established clinical diagnostic and management recommendations, the decision on the molecular testing strategy in patients with growth disturbances can
Search for other papers by Sara Ahmadi in
Google Scholar
PubMed
Search for other papers by Iñigo Landa in
Google Scholar
PubMed
-specific mortality in a cohort of 69 RAS -driven DTCs ( 17 ). In addition, two recent side-by-side publications from the same group demonstrated the power of comprehensive molecular testing in predicting tumor recurrence and refining the current methods for risk
Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Search for other papers by Ayako Sato in
Google Scholar
PubMed
Search for other papers by Katsuya Matsuda in
Google Scholar
PubMed
Search for other papers by Takahiro Motoyama in
Google Scholar
PubMed
Al-Farabi Kazakh National University, Almaty City, Republic of Kazakhstan
Search for other papers by Zhanna Mussazhanova in
Google Scholar
PubMed
Search for other papers by Ryota Otsubo in
Google Scholar
PubMed
Search for other papers by Hisayoshi Kondo in
Google Scholar
PubMed
Search for other papers by Yuko Akazawa in
Google Scholar
PubMed
Search for other papers by Miyoko Higuchi in
Google Scholar
PubMed
Search for other papers by Ayana Suzuki in
Google Scholar
PubMed
Search for other papers by Mitsuyoshi Hirokawa in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Search for other papers by Takeshi Nagayasu in
Google Scholar
PubMed
Search for other papers by Masahiro Nakashima in
Google Scholar
PubMed
1 expression were closely associated with high-grade malignancy. According to the 2017 Bethesda System for Reporting Thyroid Cytology, for category III or IV cases, molecular testing is usually recommended to obtain further diagnostic information
Search for other papers by Natalie Rogowski-Lehmann in
Google Scholar
PubMed
Search for other papers by Aikaterini Geroula in
Google Scholar
PubMed
Search for other papers by Aleksander Prejbisz in
Google Scholar
PubMed
Search for other papers by Henri J L M Timmers in
Google Scholar
PubMed
Search for other papers by Felix Megerle in
Google Scholar
PubMed
Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Search for other papers by Stephanie M J Fliedner in
Google Scholar
PubMed
Search for other papers by Martin Reincke in
Google Scholar
PubMed
Search for other papers by Anthony Stell in
Google Scholar
PubMed
Search for other papers by Andrzej Januszewicz in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Jacques W M Lenders in
Google Scholar
PubMed
Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
Search for other papers by Graeme Eisenhofer in
Google Scholar
PubMed
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland
Search for other papers by Felix Beuschlein in
Google Scholar
PubMed
paraganglioma: molecular testing and personalized medicine . Current Opinion in Oncology 2016 28 5 – 10 . ( https://doi.org/10.1097/CCO.0000000000000249 ) 10.1097/CCO.0000000000000249 26599293 11 Favier J Amar L Gimenez-Roqueplo AP. Paraganglioma and